Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

DaTscanâ„¢ (Ioflupane I 123 Injection) Now Available to Help Physicians Assess Patients with Suspected Parkinsonian Syndromes

June 28, 2011 By Bio-Medicine.Org

PRINCETON, N.J., June 28, 2011 /PRNewswire/ — GE Healthcare
today announced the availability of DaTscan™ (Ioflupane I 123
Injection), in more than 80 hospitals across the US. DaTscan is the
first FDA-approved radiopharmaceutical adjunct imaging agent to
help physicians evaluate patients with suspected parkinsonian
syndromes (PS), such as Parkinson’s disease (PD). It gives
physicians diagnostic capability that may lead to timely,
appropriate treatments for suspected PS patients.

“This is a major advance in the diagnostic imaging space. GE
Healthcare personnel are working extremely closely with hospitals
to ensure that these institutions have the proper facilities to
handle and use DaTscan and that physicians are trained properly,”
said Donald J. Quinn, Vice President and General Manager, GE
Healthcare Medical Diagnostics.

DaTscan is a Drug Enforcement Administration (DEA) Schedule II
controlled substance. Hospitals and nuclear imaging centers that
administer DaTscan must have infrastructure dedicated to quality
control, handling and dispensing of DEA Schedule II, radioactive
drugs used for diagnosis and treatment.

“We have a thorough process in place to provide institutions
with assistance in DEA-controlled substance registration, imaging
equipment set-up, and personnel training for radioactive drug
handling and patient imaging protocols,” said Quinn.

Fifty thousand to sixty thousand new cases of PD are diagnosed
in the US each year,(1) but an accurate diagnosis can take up to
six years. Many people mistakenly attribute the first symptoms of
PS, such as PD, to the normal aging process, and many have
misconceptions about diagnosis. A recent survey by the National
Parkinson Foundation found that 33 percent of Americans believe
that a blood test can detect PD, while 30 percent did not know.
Although doctors can run blood tests to help diagnose a number of
conditions, they cannot diagnose PD based on the results of a blood
test.(2) D

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech